A new database of more than 4,000 Alzheimer’s disease patients who have participated in 11 industry-sponsored clinical trials was released on Friday by the Coalition Against Major Diseases (CAMD). According to the Critical Path Institute, which oversees the coalition, "This is the first database of combined clinical trials to be openly shared by pharmaceutical companies and made available to qualified researchers around the world. It is also the first effort of its kind to create a voluntary industry data standard that will help accelerate new treatment research on brain disease, as patients with other related brain diseases are expected to be added." CAMD is a formal consortium of pharmaceutical companies, research foundations and patient advocacy/voluntary health associations, with advisors from federal agencies. The non-profit Critical Path Institute (C-Path), led by Dr. Ray Woosley, is funded by a cooperative agreement with the FDA and a matching grant from Science Foundation Arizona.
http://www.c-path.org/News/CAMDPressRelease62010.pdf